In a study analyzing a total of 219 patients with R/R B-ALL who participated in either CD19 (NCT03919240) or CD19/CD22 CAR T-cell therapy (NCT03614858) clinical trials, researchers found that patients receiving dual-target CAR-T therapy achieved a higher CR rate (98% vs. 83%) compared to those receiving single-target therapy [78]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.